Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)
The FDA approved Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, after trials showed 51.4% of adults avoided surgery for 12 months. Cardinal Health will acquire Solaris Health for $1.9 billion in cash, expanding its specialty care network. RemeGen’s telitacicept met its Phase 3 endpoint in primary Sjögren’s syndrome in China. Response Therapeutics’ RDX-002 pill curbed weight regain in a Phase 2 trial.
